Novacyt « Terug naar discussie overzicht

Novacyt de volgende biotech raket!

[verwijderd]
2
quote:

Buurvrouw nummer 2 schreef op 17 augustus 2020 14:55:

[...]

Op dit forum alleen al zijn er meermaals concurrenten hun tests gedeeld met mooie artikelen bij om 2 weken later dan te zien dat ze eigenlijk bagger zijn...

Als je kijkt Van welke schuldenberg enkele maanden geleden tot waar nu novacyt staat denk ik wel dat novacyt zich al heeft bewezen...
Ja mij moeten ze niet meer overtuigen hoor, zit er al een half jaar met trots in en ga niet lossen, zeker nu niet :).
Ben gewoon ongeduldig, het is niet de moment om zo lang stil te blijven. De UK tender, de testcase in de rusthuizen, de VS waar we al zo lang op wachten. En ook eerste keer in 5 maanden geen maandelijkse sales update.
trab33
0
het is echt veel te stil vanuit novahoek
ofwel zijn ze met iets enorm bezig ofwel zit er een overname aan te komen , ik vond het een paar maanden geleden al raar dat insiders kochten rond 3.5 a 3.8 en nadien alles veranderde qua communicatie

we zien wel wat er op ons afkomt maar het zou wel eens een enorme koersexplosie tot stand kunnen brengen
trab33
0
dat de koers een ganse dag in een bandbreedte van 7 cent kwispelt is ongezien voor dit aandeel
dat is toch geruststellend saai ;)
RW1963
1
quote:

Egomarinus schreef op 17 augustus 2020 14:44:

Intrasense zit ook weer in de startblokken.
Tja.....................half procentje erbij vandaag. Als je daar al blij van wordt?
[verwijderd]
1
quote:

Polle schreef op 17 augustus 2020 20:39:

Nieuws op bourserama ?
Er is geen nieuws hoor. Boursorama is het lezen niet meer waard, die Fransen vinden alleen maar zelf dingen uit.
Unieke_Alias
0
quote:

trab33 schreef op 17 augustus 2020 16:57:

het is echt veel te stil vanuit novahoek
ofwel zijn ze met iets enorm bezig ofwel zit er een overname aan te komen , ik vond het een paar maanden geleden al raar dat insiders kochten rond 3.5 a 3.8 en nadien alles veranderde qua communicatie

we zien wel wat er op ons afkomt maar het zou wel eens een enorme koersexplosie tot stand kunnen brengen
Komt die overname ook weer om de hoek kijken....:-)

Kan iemand mij de meerwaarde van een overname bij Novacyt uitleggen ?

Naar mijn idee hebben ze aan cash geen gebrek momenteel en sneller groeien dan zo snel als ze de afgelopen maanden gedaan hebben, lijkt me zeer onwaarschijnlijk....je hebt ook een bedrijf met gezonde mensen nodig, waar het leuk is om te werken, anders wordt het alleen maar een korte termijn succes en geen lange termijn....en dat is wat je denk ik wil.
trab33
0
bedrijven waar de cash zo snel binnenkomt staan echt wel op de kaart
en daar is in drukletters op te lezen ,,,,,,,,,,,,,,,,,,,,,,, " CHEAP TAKEOVER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,
en van mij mag dat morgen al ;)
Johny
0
Van mij mag het nog efkes duren , ik heb graag een expensive takeover :)

FDA warning over test thermofisher ? Inaccurate...
Unieke_Alias
0
quote:

trab33 schreef op 17 augustus 2020 22:23:

bedrijven waar de cash zo snel binnenkomt staan echt wel op de kaart
en daar is in drukletters op te lezen ,,,,,,,,,,,,,,,,,,,,,,, " CHEAP TAKEOVER",,,,,,,,,,,,,,,,,,,,,,,,,,,,,
en van mij mag dat morgen al ;)

Snap ik, maar dat zijn meer persoonlijke redenen...tegen de juiste prijs, vind ik een overname ook prima.
Maar een ‘inhoudelijke’ meerwaarde is er volgens mij niet....daarom geloof ik er ook niet zo in.
DeZwarteRidder
0
Optimism on Covid-19 immunity climbs as studies show antibodies protect and T-cells last longer

Fishing boat study provides first real-life example of antibodies in action

17 August 2020 • 7:00pm

Scientists are growing increasingly confident about the human immune response to SARS-CoV-2 after studies showed antibodies provide “real-world” protection against the virus and cellular immunity may be long-lasting, even in mild cases.

A study of a Covid-19 outbreak on a Seattle fishing boat involving more than 100 sailers has all but proven that antibodies provide protection against re-infection. Meanwhile, an encouraging body of evidence has found that T and B cells remain in the blood even once antibodies fade.

“This is exactly what you would hope for,” Marion Pepper, an immunologist at the University of Washington and an author on one of the new studies, told The New York Times. “All the pieces are there to have a totally protective immune response.”

“This is very promising,” echoed Smita Iyer, an immunologist at the University of California, Davis “This calls for some optimism about herd immunity, and potentially a vaccine.”

Antibodies have long been thought to protect against reinfection but the first study to use hard real-world evidence was published last week by researchers at the University of Washington.

It tracked the 122 strong crew of a fishing boat operating in the Pacific off the coast of Seattle, Washington. All were tested for both antibodies and the virus before they sailed and after. An outbreak occurred on the vessel and 104 people become infected - an attack rate of 85 per cent.

However, only those without pre-existing antibodies caught the virus. Of the three crew members who had already been exposed to the disease prior to the boat’s departure and had antibodies, none showed evidence of reinfection.

Professor Danny Altmann, of the department of immunology and inflammation at Hammersmith Hospital, Imperial College, said: "While this is a small study, it offers a remarkable, real-life, human experiment at a time when we've been short of hard-line, formal, proof that neutralising antibodies genuinely offer protection from re-infection. In short, it’s good news”.

While the findings are welcome news, key questions remain over the human immune responses to the virus - namely around how long such antibodies last. Most studies show they start to fade after just a few months.

However, there is mounting evidence that T cells and B cells, often described as “memory cells”, provide longer-lasting protection.

It was widely reported last month that researchers at the Karolinska University Hospital and University Hospital of Wales had found that people who recovered from asymptomatic or mild cases of Covid-19 may have long-term T-cell immunity against severe infection.

Similarly, another Seattle-based study published just last week found that patients who had recovered from mild forms of the virus had developed SARS-CoV-2-specific antibodies and neutralizing plasma, as well as virus-specific memory B and T cells.

These “memory cells” not only persisted but in some cases increased numerically over the three months following symptom onset.

According to the study, the T cells multiplied upon re-encounter with the virus, while the B cells expressed receptors “capable of neutralising the virus”.

As such, the authors claim that the findings demonstrate that even mild Covid-19 can elicit memory cells that provide protective immunity.

www.telegraph.co.uk/global-health/
Speculatie
0
quote:

voda schreef op 17 augustus 2020 08:47:

[...]
En DZR kwam weer langs "wippen". Die UP zou wel eens niet zo ver van de waarheid kunnen zitten. De pre staat in ieder geval wél hoger. :-)

Theor. open 3,40 08:44:27
Theor. open 3,375 08:37:57

Over een uur onder de 3.3?
Speculatie
0
quote:

DeZwarteRidder schreef op 18 augustus 2020 08:37:

Optimism on Covid-19 immunity climbs as studies show antibodies protect and T-cells last longer

Fishing boat study provides first real-life example of antibodies in action

17 August 2020 • 7:00pm

Scientists are growing increasingly confident about the human immune response to SARS-CoV-2 after studies showed antibodies provide “real-world” protection against the virus and cellular immunity may be long-lasting, even in mild cases.

A study of a Covid-19 outbreak on a Seattle fishing boat involving more than 100 sailers has all but proven that antibodies provide protection against re-infection. Meanwhile, an encouraging body of evidence has found that T and B cells remain in the blood even once antibodies fade.

“This is exactly what you would hope for,” Marion Pepper, an immunologist at the University of Washington and an author on one of the new studies, told The New York Times. “All the pieces are there to have a totally protective immune response.”

“This is very promising,” echoed Smita Iyer, an immunologist at the University of California, Davis “This calls for some optimism about herd immunity, and potentially a vaccine.”

Antibodies have long been thought to protect against reinfection but the first study to use hard real-world evidence was published last week by researchers at the University of Washington.

It tracked the 122 strong crew of a fishing boat operating in the Pacific off the coast of Seattle, Washington. All were tested for both antibodies and the virus before they sailed and after. An outbreak occurred on the vessel and 104 people become infected - an attack rate of 85 per cent.

However, only those without pre-existing antibodies caught the virus. Of the three crew members who had already been exposed to the disease prior to the boat’s departure and had antibodies, none showed evidence of reinfection.

Professor Danny Altmann, of the department of immunology and inflammation at Hammersmith Hospital, Imperial College, said: "While this is a small study, it offers a remarkable, real-life, human experiment at a time when we've been short of hard-line, formal, proof that neutralising antibodies genuinely offer protection from re-infection. In short, it’s good news”.

While the findings are welcome news, key questions remain over the human immune responses to the virus - namely around how long such antibodies last. Most studies show they start to fade after just a few months.

However, there is mounting evidence that T cells and B cells, often described as “memory cells”, provide longer-lasting protection.

It was widely reported last month that researchers at the Karolinska University Hospital and University Hospital of Wales had found that people who recovered from asymptomatic or mild cases of Covid-19 may have long-term T-cell immunity against severe infection.

Similarly, another Seattle-based study published just last week found that patients who had recovered from mild forms of the virus had developed SARS-CoV-2-specific antibodies and neutralizing plasma, as well as virus-specific memory B and T cells.

These “memory cells” not only persisted but in some cases increased numerically over the three months following symptom onset.

According to the study, the T cells multiplied upon re-encounter with the virus, while the B cells expressed receptors “capable of neutralising the virus”.

As such, the authors claim that the findings demonstrate that even mild Covid-19 can elicit memory cells that provide protective immunity.

www.telegraph.co.uk/global-health/
Dat klinkt positief - dit zou heel mooi zijn.
Tommaco
0
In dit artikel staat dat Qiagen 95 miljoen aan Thermo Fisher moet betalen en niet omgekeerd zoals in vorige berichtgevingen stond:

www.prnewswire.co.uk/news-releases/th...
Tommaco
1
De toekomst van het testen:

We staan niet tussen de toppers:

Top Key Vendors of this Market are:
Biomérieux , Danaher Corporation , Becton, Dickinson and Company , Abbott , Roche Diagnostics (A Subsidiary of F. Hoffmann-La Roche Ltd.) , Bruker , Hologic , Bio-Rad , Qiagen , Thermo Fisher Scientific , Agilent , Merck KGaA , Shimadzu , 3M , Neogen

scientect.com/news/141102/massive-gro...
Erg chebbi
0
Thnx Tommaco!
Naar dit overzichtje vroeg ik een paar dagen terug #dtv
Ga het zeker bestuderen.

NB. Als er geen nieuws komt, gaan we dan naar de 3.1x? of gaan we omhoog op de approval. Die komt toch zeker wel snel..? Bliksem!
70.375 Posts, Pagina: « 1 2 3 4 5 6 ... 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 ... 3515 3516 3517 3518 3519 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 26 apr 2024 17:28
Koers 0,819
Verschil +0,023 (+2,89%)
Hoog 0,819
Laag 0,766
Volume 159.483
Volume gemiddeld 178.863
Volume gisteren 131.739

EU stocks, real time, by Cboe Europe Ltd.; Other, Euronext & US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront